Azacitidine plus venetoclax boosts response rates in therapy-related high-risk MDS, enabling transplant bridging despite frequent severe cytopenias and infection risk.

For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).

Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

MPNs involve overproduction of blood cells, while MDS results in poorly formed cells, affecting blood cell function and counts. Diagnosis requires blood tests, bone marrow biopsy, and genetic testing ...

Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases ...